Why “waiting for Phase III” is the most expensive mistake in biotech

Approval is only the beginning

Regulatory approval is a critical milestone—but it doesn’t guarantee patient access, reimbursement or commercial success.

Download the white paper

Why waiting for Phase III is the most expensive mistake in biotech white paper

Today’s payers and HTA bodies expect evidence that goes beyond clinical efficacy, including real-world outcomes, comparative effectiveness and economic value. Without it, even promising therapies can face reimbursement restrictions, pricing pressure and slow adoption.

Learn why early evidence planning is essential to successful biotech commercialization.

In this white paper, you’ll discover:

Why approval alone is no longer enough

How evidence gaps can delay access and uptake

The growing role of real-world evidence (RWE)

Risks of waiting until late-stage development to address market access

Strategies for integrating evidence planning from Phase I onward

Build evidence early. Maximize value later.

The most successful biotech companies don’t wait until Phase III to think about market access. They build the evidence needed for reimbursement, adoption and long-term commercial success from the start.

Download the white paper to learn how early evidence planning can help turn regulatory approval into real-world impact.

Get your copy

Plan earlier evidence, download the white paper